New pill takes on Virus-Linked lymphoma in early trial
NCT ID NCT06789159
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 40 times
Summary
This early-phase trial tests an oral drug called VK-2019 in 30 adults with a type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. Participants will take one of three daily doses (600, 1200, or 1800 mg) in 28-day cycles. The main goal is to find the safest dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Kentucky
Lexington, Kentucky, 40506, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VK-2019 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment option for people with a hard-to-treat type of lymphoma linked to the Epstein-Barr virus.
What could go wrong
This is a very early Phase Ib trial with only 30 people, focused on safety and dosing. It may not show enough benefit to move forward, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.